p akt (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
99
Structured Review
Cell Signaling Technology Inc
p akt
P Akt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 17211 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p+akt+ser473/Phospho-Akt+(Ser473)+XP+Rabbit+mAb/pmc13018931-113-24-27
Average 99 stars, based on 17211 article reviews
P Akt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 17211 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p+akt+ser473/Phospho-Akt+(Ser473)+XP+Rabbit+mAb/pmc13018931-113-24-27
Average 99 stars, based on 17211 article reviews
p akt - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
other:Article Title: Effects of branched-chain amino acids on iron deficiency-induced muscle atrophy Article Snippet: Article Title: Dietary energy levels regulate feed intake of broilers through the brain-gut axis Article Snippet: Western Blot:Article Title: Attempt to control head and neck cancer through medium-molecular weight drug discovery Article Snippet: Background: Head and neck squamous cell carcinoma (HNSCC) arises from the squamous epithelium of the head and neck region, comprising heterogeneous lesions with distinct risk factors and diverse genetic and epigenetic alteration patterns.. HNSCC is often difficult to control when lymph node metastasis has occurred, and treatment outcomes remain unsatisfactory.. Elucidating the genetic and epigenetic profiles of cancer-associated genes is essential for improving clinical outcomes, yet to date the key molecules driving HNSCC progression remain Article Title: Discovery of triazolyl azabicyclo[3.1.0]hexane derivative as an autotaxin inhibitors for the treatment of pulmonary fibrosis. Article Snippet: Autotaxin (ATX), the enzyme responsible for generating lysophosphatidic acid (LPA), is a validated target for fibrosis and cancer immunotherapy.. Current ATX inhibitors face challenges related to insufficient efficacy or safety concerns, reflecting trade-offs between zinc engagement and selectivity.. Here, we report a rigid triazolylazabicyclo[3.1.0]hexanyl–oxadiazolyl-pyrimidine scaffold developed through structure-based design, designed to potentially enhance ATX selectivity by promoting defined binding geometry. Immunohistochemistry:Article Title: Discovery of triazolyl azabicyclo[3.1.0]hexane derivative as an autotaxin inhibitors for the treatment of pulmonary fibrosis. Article Snippet: Autotaxin (ATX), the enzyme responsible for generating lysophosphatidic acid (LPA), is a validated target for fibrosis and cancer immunotherapy.. Current ATX inhibitors face challenges related to insufficient efficacy or safety concerns, reflecting trade-offs between zinc engagement and selectivity.. Here, we report a rigid triazolylazabicyclo[3.1.0]hexanyl–oxadiazolyl-pyrimidine scaffold developed through structure-based design, designed to potentially enhance ATX selectivity by promoting defined binding geometry. Purification:Article Title: Discovery of triazolyl azabicyclo[3.1.0]hexane derivative as an autotaxin inhibitors for the treatment of pulmonary fibrosis. Article Snippet: Autotaxin (ATX), the enzyme responsible for generating lysophosphatidic acid (LPA), is a validated target for fibrosis and cancer immunotherapy.. Current ATX inhibitors face challenges related to insufficient efficacy or safety concerns, reflecting trade-offs between zinc engagement and selectivity.. Here, we report a rigid triazolylazabicyclo[3.1.0]hexanyl–oxadiazolyl-pyrimidine scaffold developed through structure-based design, designed to potentially enhance ATX selectivity by promoting defined binding geometry. Incubation:Article Title: Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability. Article Snippet: Protein concentration was determined using the Pierce bicinchoninic acid assay (Life Technologies #23225) and 40 μg of protein were loaded per lane on a 4-12% Bis-Tris or 3-8% Tris-Acetate gel (Life Technologies #NP0323 and #EA03785). .. Proteins were transferred onto polyvinylidene fluoride membranes (Life Technologies IB24002) using an iBlot 2 at 20V for 6-12 minutes and subsequently incubated in 5% BSA, 1X TBST AR TI CL E IN P RE SS (Teknova #T9511) prior to probing with one of the following primary antibodies: RPS15 (1:1000 dilution; #PIPA562977, Thermo Fisher Scientific), RPL5 (1:1000; #14568S, Cell Signaling Technology), ATM (1:1000; #2873, clone D2E2, Cell Signaling Technology), p-ATM Ser1981 (1:250; #AF1655, R&D), SMC1 (1:1000; #4802, Cell Signaling Technology), p-SMC1 Ser957 (1:1000; #4805, clone 5D11G5, Cell Signaling Technology), Chk2 (1:1000; #sc-5278, clone A12, Santa Cruz), p-Chk2 Thr68 (1:500; #2661, Cell Signaling Technology), Chk1 (1:1000; #sc8408, clone G-4, Santa Cruz), p-Chk1 Ser345 (1:500; #2341, Cell Signaling Technology), γH2AX Ser139 (1:1000; #05-636, clone JBW301, Millipore; and 1:1000; #2577, Cell Signaling Technology), p53 (1:1000; #9282 and #2524 [clone 1C12], Cell Signaling Technology), p21 (1:500; #64016, Cell Signaling Technology), cyclin A (1:200, #sc-239, clone BF683, Santa Cruz), AKT (1:1000, #4298, clone 40D4, Cell Signaling Technology), |